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Abstract
There is a great desire to relate the patterns
of endogenous peptides in blood to human dis-
ease and drug response. The best practices for
the preparation of blood fluids for analysis are
not clear and also relatively few of the peptides
in blood have been identified by tandem mass
spectrometry. We compared a number of
sample preparation methods to extract endoge-
nous peptides including C18 reversed phase,
precipitation, and ultrafiltration. We examined
the results of these sample preparation
methods by matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) and
liquid chromatography-tandem mass spectrom-
etry (MS/MS) using MALDI-TOF/TOF and
electrospray ionization-ion trap. Peptides from
solid-phase extraction with C18 in the range of
hundreds of femtomoles per spot were detected
from the equivalent of 1 µL of serum by
MALDI-TOF. We observed endogenous serum
peptides from fibrinogen α- and β-chain, com-
plement C3, α-2-HS-glycoprotein, albumin,
serine (or cysteine) proteinase inhibitor, factor
VIII, plasminogen, immunoglobulin, and other
abundant blood proteins. However, we also
recorded significant MS/MS spectra from tumor
necrosis factor-α-, major histocompatibility com-
plex-, and angiotensin-related peptides, as well
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Introduction
A mass spectrometer (MS) can be used to
identify the peptides in serum, plasma, or other
biological fluids (1,2) as an aid in diagnosis of
disease or to identify physiologically relevant
molecules (3,4). The patterns of low-molecular
mass peptides in samples from normal and dis-
eased populations have been compared using
time-of-flight (TOF) MS of unfractionated
serum bound to a chromatographic surface on
the matrix-assisted laser desorption/ionization
(MALDI) target (5). The peptide/protein pat-
terns in unfractionated serum have been shown
to vary considerably during sample handling
making their clinical use as biomarkers difficult
(6). Serum fractionated by C18 partition chro-
matography produced peptide patterns by
MALDI-TOF in agreement with classical bio-
chemical and immunological investigations (7).
Some of the endogenous peptides from serum
have been identified by tandem MS (MS/MS)
(7–10). Fetal serum contains growth factors that
can stimulate cell lines to grow in culture. Some
of these factors might be low-molecular mass
polypeptides. Proteolytic fragments of larger
molecules that circulate in the blood may have
profound regulatory effects. For example, the
proteolytic processing of collagen and related
molecules produces fragments with roles in
angiogenesis, cell growth, and complex regula-
tory processes that remain to be better defined
(11). Proteolytic processing of fibrinogens
releases fragments that have been associated
with acute events, such as coronary thrombosis
(12) or the effects of cancer (13–15). 
To date, there has been no comparison of the
methods used to extract polypeptides from
blood fluids for MS/MS analysis. Richter et al.
used hemofiltrate depleted of larger proteins
to construct a database of circulating human
peptides (16). Reversed-phase chromatography
has been used to efficiently collect peptides for
serum profiling (3,7,17). Polypeptides have
also been isolated by precipitation with organic
solvents (10) or from the carrier protein albu-
min (18,19). Recently, membrane filter plates
have been used to solid-phase extract (SPE) the
endogenous peptides from serum prior to
identification using TOF/TOF (9). A key step
in developing such methodology will be to
determine what pool of peptides in serum are
bound to carrier proteins, such as albumin
(18–20). We compared sample preparation
methods for detecting peptides from serum by
MS. Polypeptides from fetal serum were
extracted by a variety of methods and com-
pared by MALDI-TOF MS prior to liquid chro-
matography (LC)-MS/MS with electrospray
ionization (ESI)-ion trap and MALDI-TOF/
TOF identification.
Materials
1. Tissue culture grade fetal bovine calf serum
was obtained from GIBCO (Burlington,
Ontario, Canada) and is produced by rapid
clotting in bags, separation, and cooling to
near freezing point followed by utrafiltra-
tion. We did not subsequently heat inactivate
the serum. 
2. Magnetic beads with C18, SAX, WAX, SCX,
HIC, and other bonded phases were obtained
from Bruker Daltonics (Billerica, NJ). 
as peptides from collagens and other low-
abundance proteins. Amino acid substitutions
were detected and a phosphorylated peptide
was also observed. This is the first time the
endogenous peptides of fetal serum have been
examined by MS and where peptides from 
low-abundance proteins, phosphopeptides,
and amino acid substitutions were detected.
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3. C18 resins were also obtained from Millipore
(Bedford, MA) or Vydac (Hesperia, CA). 
4. Amicon ultrafiltration membranes were
obtained from Millipore. 
5. Capillary C18 reversed-phase columns were
obtained from Vydac. 
6. P10 gel, DEAE-Blue resin, and sodium dode-
cyl sulfate-polyacrylamide gel electrphoresis
standards were obtained from Bio-Rad Lab-
oratories (Hercules, CA). 
7. Solvents were obtained from Caledon Labo-
ratories (Georgetown, Ontario, Canada). 
8. Cibacron blue resin and all other salts and
reagents were obtained from Sigma-Aldrich-
Fluka (St. Louis, MO) except where indicated.
Methods
Chromatography
Capacities were calculated and loading and
elution conditions were in accordance with
manufacturer’s instructions except where indi-
cated. Partition chromatography and SPE with
C18 reversed-phase resin was run by gravity
drip except where indicated.
Preparative C18 Chromatography
Batch chromatographic separations with
C18 magnetic beads were performed according
the manufacturer’s instructions and buffers
(Bruker), as previously described (17). Briefly,
beads were equilibrated with the appropriate
binding buffer before incubation in a volume
of serum (equal to the packed volume) diluted
in 10 vol of binding buffer. The serum sample
was mixed with binding buffer and bound to
the beads before washing in the binding
buffer. Beads were collected with a magnetic
96-well plate holder before eluting with the
appropriate buffer and collecting the eluant
from the magnetic plate into 1-mL centrifuge
tubes. Brief centrifugation at 12,000g ensured
complete removal of particles. To accurately
estimate the peptides in the equivalent of 1-µL
of serum and for loading gels, 50 µL of serum
were diluted in binding buffer for immobi-
lization onto 100 µL of C18 resin-packed
volume and then eluted in 100 µL. Two micro-
liters of the eluant (equivalent to 1 µL of
serum) were spotted on MALDI plates. Alter-
natively, the eluate was dried in a speed vac. 
Organic Solvent Precipitation
Serum samples were precipitated with 5 vol
of acetonitrile on ice for 15 min prior to spin-
ning at 12,000g for 15 min (10). The super-
natant and pellet were separated and the
supernatant was dried under vacuum. Some
samples were treated with 2 mM dithiothreitol
(DTT) prior to organic solvent precipitation or
SPE with C18.
Ammonium Sulfate Precipitation
Serum was precipitated using 4 vol of satu-
rated ammonium sulfate on ice for 15 min fol-
lowed by centrifugation at 15,000g for 15 min.
The supernatant and pellet were collected into
separate tubes.
Dye Affinity Chromatography
DEAE-Blue and Cibacron Blue resins were
loaded with sample in hypotonic buffer 
(20 mM Tris, pH 8.0, with 40 mM NaCl) or
physiological buffer (1X phosphate-buffered
saline[PBS], pH 7.3) before washing in load-
ing buffer and elution with 1 M NaCl, as
previously described (21).
Size Exclusion Chromatography
P10- and G25-size exclusion media were
used in the batch mode. Serum or serum
diluted fivefold in water or PBS was equili-
brated with an equal volume of exclusion
media on ice. The resin was collected by brief
centrifugation, rapidly resuspended in water,
repelleted, and the superanatant discarded.
The resin was then resuspended in an equal
volume of water and allowed to equilibrate on
a Ferris wheel for 15 min before collecting the
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supernatant. The process was repeated twice
to yield three fractions. The peptides were
then loaded on gels or collected over C18 for
MALDI or LC-ESI-MS/MS analysis.
Ultrafiltration
Amicon ultrafiltration membranes were used
as previously described (20). Briefly, sera were
diluted to a final concentration of 50 mM ammo-
nium bicarbonate, pH 8.3, with 20% v/v ace-
tonitrile. The solution was ultrafiltered through
YM 30-kDa nominal molecular-weight-limit fil-
ters under centrifugation at 12,000g and the 
filtrate was collected by C18 (20). 
Matrix-Assisted Laser Desorption/Ionization
Time-of-Flight Mass Spectrometry
Endogenous peptide samples collected from
all prefractionation schemes were prepared for
MALDI analysis by collection over C18
reversed phase resin and spotted onto a stain-
less steel target for an Ultraflex MALDI-
TOF/TOF (Bruker). The eluted peptides were
dried onto stainless steel targets and, after
allowing all the samples to dry evenly, the
energy-absorbing matrix cyano-4-hydroxy cin-
namic acid (CHCA) was applied for collection
of MS spectra. An automatic acquisition mode
was used to collect data from the various
treatments under identical parameters.
Liquid Chromatography-Electrospray 
Ionization Tandem Mass Spectrometry
Endogenous peptide samples collected from
all prefractionation schemes were prepared for
ESI analysis by collection over C18 reversed-
phase resin and analyzed over a 90-min gradi-
ent from 5 to 65% acetonitrile at a flow rate of
2 mL/min with an Agilent 1100 series capillary
pump (Agilent, Palo Alto, CA) through an Agi-
lent 150 × 0.3 mm C18 column. Peptides sepa-
rated by capillary high-performance LC were
ionized via a metal needle electrospray head in




Endogenous peptide samples collected from
prefractionation schemes were analyzed over
a 30-min gradient from 5 to 65% acetonitrile at
a flow rate of 2 mL/min with an Agilent 1100
series capillary pump through an Agilent 150
× 0.3 mm capillary C18 column. Peptides were
separated onto a stainless steel MALDI plate
for Ultraflex MALDI-TOF/ TOF analysis, as
described here previously. MS/MS spectra
were collected using CHCA as a matrix. 
Correlation Analysis
The resulting ESI-MS/MS spectra were ana-
lyzed by X-Tandem (22) with –1 Da and +3 Da
from parent peptide as tolerance of the parent
mass or likely isotopes in the search parameters
and 0.4 Da error in the fragments. The MALDI-
MS/MS data were searched by MASCOT (23)
with the default settings. The default-expected
value for significance by X-Tandem is E-1, but
in this study we only accepted peptides with a
score of E-2 or lower. The database was the
bovine RefSeq database downloaded from the
National Center for Biotechnology Information.
Because no exogenous enzymes were used to
digest these samples, we performed the search
with no enzyme. Searches of nonphysiological
databases yielded few significant hits at these
expectation values. 
Results
Serum was prepared by SPE with C18
reversed phase or by precipitation with ace-
tonitrile or ammonium sulfate. We compared
the profile of the polypeptides in the extracts.
We also examined serum dealbuminized with
DEAE-Blue and Cibacron Blue dye-binding
resins. Size exclusion chromatography resins,
such as P10 and G25, and ultrafiltration mem-
branes were also compared. The extracts from
these methods were further treated with C18
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reversed phase prior to LC-MS/MS. The LC-
MS/MS was performed by both LC-ion trap
and LC-TOF-TOF. 
Solid Phase Extraction With C18
We examined the collection of serum pep-
tides with C18 for extraction from the solid
phase before resolution on MALDI-TOF. We
observed that DTT treatment prior to SPE
altered a few aspects of the MALDI-TOF spec-
trum (not shown). We found that reversed
phase extraction of nonreduced samples could
be used to produce samples that permitted the
direct detection of endogenous peptides when
the sample was deposited on a single MALDI
target spot (Fig. 1).
Comparison of Methods
Acetonitrile Precipitation
We precipitated serum with acetonitrile and
compared the polypeptides in the supernatant
vs the pellet, by MALDI-TOF (10). About 1 µg
of protein and peptides was collected by
reversed-phase C18 resin and loaded on metal
plates with CHCA matrix. We observed the
presence of peptides in the organic supernatant
Fig. 1. MALDI-TOF spectrum of peptides collected by
C18 recorded with a TOF-TOF.
but the signal-to-noise ratios were much higher
in the pellet by MALDI-TOF (Fig. 2A,B). 
Ammonium Sulfate
Proteins from ammonium sulfate precipitates
typically retain enzyme activity and, therefore,
are not strongly denatured. A wide range of
peptides were observed in the supernatant and
showed some differences with the pool of pep-
tides in the pellet, but the major peptides were
shared and there were much higher signal-to-
noise ratios in the pellet (Fig. 2C,D). 
Dye-Binding Chromatography
We determined if endogenous peptides
were selectively bound to albumin by dye
affinity chromatography in hypotonic (20 mM
Tris, pH 8.0, with 40 mM NaCl) and physio-
logical buffers (1X PBS, pH 7.4) using both
DEAE Blue and Cibacron Blue resin. We
observed that many peptides eluted in the
bovine serum albumin (BSA)-depleted frac-
tion of serum that flowed through the dye-
binding column. MALDI-TOF MS of the
flow-through and retained fractions showed
that the dye resin did not selectively retain
many peptides (Fig. 2E,F) (Cibacron Blue
result shown).
Size Exclusion
The components of fetal bovine serum were
separated on the basis of their capacity to pen-
etrate the size exclusion resins P10 and G25. A
similar range of peptides was observed in the
fraction that penetrated the beads compared
to the fraction that did not penetrate the beads
(Fig. 2G,H) (P10 result shown). 
Ultrafiltration
To determine if peptides could be separated
from high-mass components, we employed
ultrafiltation with and without the presence
of 20% acetonitrile. The presence of acetoni-
trile did not seem to affect strongly the distri-
bution or intensity of small peptides (Fig. 2I,J).
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Fig. 2. (Opposite page) The selective enrichment of low-mass polypetides by SPE after precipitation, chro-
matography, and ultrafiltration. (A) MALDI-TOF spectra of the acetonitrile supernatant and (B) pellet; (C)
MALDI-TOF spectra of the ammonium sulfate supernatant and (D) pellet; (E) MALDI-TOF spectra of the
depleted flow through volume and (F) retained albumin-containing fractions from Cibacron Blue chromato-
graphy in hypotonic salts at pH 8.0. (G) MALDI-TOF spectra of the excluded volume and (H) the penetrat-
ing volume of P10 chromatography; (I) MALDI-TOF spectra of the ammonium bicarbonate filtrate vs (J) the
filtrate with ammonium bicarbonate and 20% acetonitrile.
Table 1
The Protein Concentration of the Sample 
Preparation Schemes Described in the Material
and Methods Prior to MALDI and ESI Analyses












YM30 ACN Cake 3.23




AS, anmonium sulfate; ACN, acetonitrile.
The protein concentrations of the various frac-
tions are shown in Table 1.
Sample Detection Limit
In general, the C18 method was the simplest
and fastest way to collect peptides from serum.
We found that the majority of peptides in serum
were observed at less than m/z 2300 (Fig. 3A).
We examined the sensitivity of detecting serum
peptides and found that peptides extracted
from the equivalent of 1 µL of serum produced
strong signal-to-noise ratios and showed a 
complex peptide mass distribution with many 
analytes well resolved by MALDI-TOF (Fig. 3B).
We compared the spectra from 1 µL of serum to
that of the matrix alone and observed that the
matrix ions were not prominently displayed in
the MALDI spectra of serum. The use of an
equivalent to 1 µL of serum resulted in robust
detection; no significant advantage was observed
with amounts larger than 5 µL.
Analyte Detection Limit 
We used a human fibrinogen β peptide as
both an external and internal standard to
estimate the levels of endogenous bovine
fibrinogen β peptides in 2 µL of serum on a
MALDI target spot. We observed that as little
as 25 fmol of the human Glu-fibrinogen 
peptide (EGVNDNEEGFFSAR) could be
detected in the serum peptide mixture, along
with other peptides, including those of a
bovine fibrinogen β-chain peptide (QFPT-
DYDEGQDDRP). We observed that 300–400
fmol of the Glu-fibrinogen peptide provided
roughly a similar response compared to the
endogenous fibrinogen β-chain peptide from
the equivalent of 2 µL of serum (Fig. 4A).
When the instrument was externally stan-
dardized with purified human Glu-fibrinogen,
we observed roughly the same response from
100 fmol of the human Glu-fibrinogen as the
endogenous levels of bovine β fibrinogen
peptide. In a separate experiment, we con-
firmed the presence of β fibrinogen peptides
by LC-ESI. In Fig. 4B,C, we show one of the
most intense ions that mapped to fibrinogen
B peptide and the fragmentation spectra
showing +1 ions that matched well with the
predicted series from the peptide TDY-
DEGQDDRP.
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Fig. 3.The distribution of peptides from fetal calf serum
after collection by SPE with C18 reversed phase from 
1 µL of serum. One hundred microliters of serum were
prepared by SPE with C18 and 1/100 of the product
loaded onto a single MALDI target spot. (A) SPE with
C18 yields peptides with a mass distribution of about
1000 to 2300 Da with the major peptides in the range
1600 to 2200 m/z. (B) Closer look at the lower-
abundant peptides in 1 µL of serum. Closer examina-
tion of the spectra reveals that there are some
lower-abundance peptides in the spectrum. Internal
standardization experiments showed that detection of
exogenous peptides was lost into the grass between 10
to 25 fmol on a single spot (not shown).
MALDI Reproducibility
We recorded the MALDI-TOF spectra of
peptides collected from serum by SPE with
Fig. 4. MS and MS/MS spectra of a fibrinogen beta pep-
tide collected by SPE with C18 reversed-phase chro-
matography. (A) The internal standardization of the
MALDI spectrum from C18 SPE showing endogenous
fibrinogen β peptide and exogenously added human
glu-fibrinogen peptide. (B) The resolution of fibrinogen
β peptide by LC-ESI ion trap. The peptide eluted at
approx 44.5 min into the 90-min gradient. The MS
spectra showing the parent 2+ ion at 655.7 m/z. (C)
The collision-induced dissociation fragmentation spec-
tra showing the remaining parent ion and product ions
that correlated with fibrinogen β peptide.
C18 chromatography (Fig. 5). The peptides
that eluted from reversed-phase resin with 25%
acetonitrile prominently included fibrinogen
peptide A (FPA), a previously demonstrated
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Fig. 5. The reproducibility of the MALDI spectra from
serum prepared by SPE with C18 reversed-phase chro-
matography recorded with a Bruker TOF. A sample was
broken into 100-µL aliquots and then frozen. Frozen
aliquots were thawed, SPE with C18, and prepared for
MALDI-TOF analysis. The position of an FPA cluster
centered on 1218 m/z is shown by the black arrow and
detailed view shown in the inset of the top panel.
marker of myocardial infarction in serum (7)
(Fig. 5, inset). The peptides corresponding to
FPA are shown in the box and are enlarged in
the inset. We were interested in estimating the
reproducibility of MALDI peptide patterns.
We show the results from six consecutive
MALDI spots from six previously frozen
aliquots of the same serum. We observed that
extracted peptides spotted onto MALDI targets
produced a reproducible pattern of ions,
including larger peptides, such as the β fib-
rinogen fragments and FPA (Fig. 5). From this
experiment, we found that the relative varia-
tion in the intensity of α fibrinogen peptides
is not large but the absolute variation is 
significant.
Identification of C18 Peptides by Offline
LC-MALDI-TOF/TOF
To better detect and identify lower-abundance
components of MALDI-TOF spectra, we pre-
pared serum by SPE with C18 and separated
the components by offline LC onto metal
plates prior to MALDI-TOF/TOF. The pep-
tides were separated over a 30-min LC gradi-
ent from 5 to 65% acetonitrile at 2 µL/min
onto metal plates and subsequently mixed
with CHCA and examined by MALDI-
TOF/TOF. Separation of the peptides by
LC resulted in MALDI spots containing indi-
vidual peptides and groups of chromato-
graphically similar peptides (Fig. 6). Offline
separation permitted identification of many
peptides that were not prominent in the spec-
tra of the batch C18 sample. The peptides
LVKSQVNDNEEGFFSARGH at 2191 D, TDY-
DEGQDDRPKVGLGA at 1835 D, and TDY-
DEGQDDRP at 1310 Da were identified from
the parent ion mass and fragmentation pat-
terns produced by the TOF/TOF (not shown).
A 1466-Da FPA was essentially purified onto a
single MALDI target spot and subsequent
MS/MS fragmentation resulted in a clear set of
fragments corresponding to the FPA-like pep-
tide TKESDFLAEGGGVR (Fig. 7A). Similarly,
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a peptide at 1518 m/z showed MS/MS spec-
tra correlating with the peptide SDPAGGE-
FLAEGGGVR (Fig. 7B); a peptide at 1207 m/z
correlated to EGDFLAEGGGVR and another
homolog of FPA DPPSGDFLTEGGGV at 1232
Da was also observed (not shown). We detected
a phosphopeptide DPSGEGDFLAE GGGVR at
1546 m/z with a MOWSE score of 94 (Fig. 7C).
The parent molecule, fibrinogen, is an abun-
dant protein in serum and its presence has
previously been confirmed by MS of serum
digested with trypsin and separated by two-
dimensional-LC (21,24,25). In addition, the
presence of angiotensin-like peptide II DRVY-
IHPF at 1046 Da, which differs from the
common MS standard DRVYVHPFHL, was
apparently very weakly detected with a
MOWSE score of 43 (Fig. 7D). The different
isoforms, posttranslational modifications of
FPA we have detected here with automatic
MS/MS identification by TANDEM or




We tested extractions with C18 bound to
paramagnetic beads in the 96-well format (17)
or with more labor-intensive methods using
commercial preparative microcolumns (ZipTips)
and by batch collection over-magnetic and non-
magnetic C18 resin and found the results to be
similar. The TIC profile for the C18 beads is
shown in Fig. 8A. C18 resin seemed to effi-
ciently capture FPA (Fig. 8B,C) with confident
correlation scores by MASCOT or X-TANDEM
using no enzyme searching parameters, consis-
tent with previous results (3,7,17). We found
that, for the identification of the fibrinogens and
other serum proteins, C18 was a good choice
and the combination of C18 with batch columns
(SCX, WAX, SAX, HIC, and others), ultrafiltra-
tion, or organic solvent precipitation resulted in
the identification of common serum proteins
including fibrinogen α- and β-chain. In general,
Fig. 6. Offline LC separation and detection of lower-
abundance endogenous peptides from fetal bovine
serum. Panels show selected offline LC-MALDI
target MS spectrum illustrating the detection of
lower-abundance polypeptides after SPE with C18
followed by capillary C18 separation of 1 µg of
extracted peptides in more than 30 MALDI target
spots over the course of 30 min from 5 to 65%
acetonitrile.
poorer results were obtained with samples pre-
pared with dye-binding or size-exclusion media
(Table 3) and from ammonium sulfate super-
natants. In agreement with others, we found
that polypeptides may cofractionate with serum
06_Williams.qxd  11/21/06  3:18 PM  Page 76
Volume 2, 2006 ________________________________________________________________ Clinical Proteomics
Fig. 7. Peptides separated over the course of offline capillary C18 LC over metal target plates analyzed by
MALDI-TOF with fragmentation and identification by TOF/TOF. Panels: (A) the 1466 m/z peptide isolated
on a MALDI target spot by offline analytical C18 LC separation with MS/MS spectra indicating the peptide
TKESDFLAEGGGVR; (B) peptide at 1518 m/z with MS/MS spectra indicating the peptide SDPAGGE-
FLAEGGGVR; (C) detection of a phsophorylated form of FPA DPSGEGDFLAEGGGVR; (D) putative iden-
tification of angiotensin-like peptide II DRVYIHPF at 1046 m/z.
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Table 2
Sequence Variations and Amino Acid Substitutions in FPA
as Detected by MADLI-TOF/TOF and ESI-Ion Trap Analysis 




















Note that MALDI analysis of fetal calf serum identified the
FLAEGGGVR sequence whereas ESI analysis seemed to have identified
the FLTEGGGVR. In contrast, both MALDI and ESI analysis of human
serum revealed the FLAEGGGVR sequence (see Marshall et al. 2003 [7]).
albumin (18,26). MALDI ionization seemed to
produce the best spectra from FPA isoforms
containing the sequence FLAEGGGVR, similar
to MALDI experiments with human serum. In
LC-ESI ion-trap experiments the best MS/MS
spectra were usually obtained from peptides
containing the sequence FLTEGGGVR, in con-
trast to previously published human LC-ESI-
MS/MS data (7).
Correlation Analysis of Peptides
We used X-TANDEM (22) to correlate
endogenous serum peptides to canonical blood
proteins and proteins that are apparently not
in high abundance in blood fluids (27). This
algorithm is designed to detect peptides and
modified peptides, but does not contemplate
the detection of peptides joined by cystine
bridges. We present these correlations with log
expectation values of –2 or lower in Table 3,
but we do not accept these results as unequiv-
ocal for the reasons outlined in the Discussion
and previously (8). We found some peptides
from known blood proteins, such as comple-
ment C3 and α-2-HS-glycoprotein, albumin,
serine (or cysteine) proteinase inhibitor, globu-
lins, and other well-known blood proteins such
as major histocompatibility complex molecules,
clotting factor VIII, and plasminogen (Table 3).
We also detected single peptides from many
other blood proteins including immunoglobu-
lins, C1Q, α-2-macroglobulin, apolipoproteins,
soluble receptors, disintegrins, fibronectins, thy-
roglobulin, ankyrins, proteoglycan, cadherin,
06_Williams.qxd  11/21/06  3:18 PM  Page 78
Volume 2, 2006 ________________________________________________________________ Clinical Proteomics
Endogenous Peptides From Serum _____________________________________________________________ 79
from five different isoforms from the collagen
superfamily (Table 4) and we obtained one
apparently significant peptide from the func-
tionally and structurally related protein scav-
enger receptor B (Table 2). Few of these
peptides were from the common high-abun-
dance structural collagens I, II, and III, which
would be expected if these peptides merely
represented contamination from tissues.
Rather, they were from the lower abundance
collagens IV, V, VII, and XXVII that are associ-
ated with diverse regulatory functions on the
cell surface or in the extracellular space (Table 3)
(11). In addition, we observed peptides that
could be weakly correlated to known antibody
variable chains by MASCOT and with
MOWSE scores more than 40 to peptides from
many proteins that are not definitively known
to exist in blood (not shown). 
Discussion
We identified endogenous peptides from
sera and have used MALDI MS/MS and LC-
MALDI MS/MS to identify families of frag-
ments from albumin, serum amyloid A,
apolipoprotein E and CIII, clusterin, comple-
ment C3 and 4a, and fibrinogen α (see Mar-
shall et al. 2004 [8] and US Patents especially
20020161180, 20020161187, 20060024671, and
many others originally filed in April 2001) and
these results have recently been confirmed by
two other groups (9,28). Similarly, we first
showed that the mass spectra of serum pep-
tides that differ between physiological states
change with time and were the result of the ex
vivo action of endo- and exopeptidases and
that fresh plasma has fewer peptides than
fresh serum (7) and these observations and
hypothesis have been confirmed by other
groups (9,28). However, our position is that
this type of pattern analysis work is only for
discovery experiments. Biomarkers discovered
by MS and LC-MS should show differences by
using standard analysis of variance of each
peptide mass and followed by leave-one-out
Fig. 8. Capillary LC-ESI ion trap analysis of endoge-
nous peptides by SPE with C18. Panels: (A) the LC-
ESI total ion current of peptides obtained from fetal
calf serum using C18 SPE; (B) the resolution of FPA
peptide by LC-ESI-ion trap. The peptide eluted at
approx44.5 min into the 90-min gradient. The MS
spectra showing the parent 2+ ion at 746 m/z; (C)
the collision-induced dissociation fragmentation spec-
tra showing the remaining parent ion and the prod-
uct ions that correlate with FPA.
cellular adhesion, cell signaling, and many
other proteins (not shown) including peptides
mapping to known cancer biomarkers or asso-
ciated with mechanisms or metabolic response
to cancer. To illustrate this we show one peptide
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Table 4 
Endogenous Fragments of the Collagen Superfamily Detected by LC-ESI MS/MS of Fetal Calf Serum 
AA AA Protein 
RefSeq Description start stop M + H expect Peptide
XP_595835.1 Collagen α 2(V) 87 110 2289.1 –2.1 AQMAGLDEKSGLGSQVGLMPGSVG
XP_604487.1 Type IV α 6 100 115 1427.8 –3.7 GEPGLPGPPGLLGLPG
collagen
XP_583692.1 Type VII 2343 2358 1386.7 –1.3 PGPPGSAGVPGVPGLK
collagen
XP_591171.1 Type IV 20 39 1839.9 –1.2 GFQGPPGPPGIPGPIGQPGL
collagen α 5
XP_602219.1 Collagen, type 294 305 1180.6 –1.1 SPVSPASSPRPV
XXVII, α 1
The endogenous peptides were extracted from fetal calf serum as described in the materials and methods and
separated at 2 µL/min through a metal needle into a Bruker HCT ion trap. Expect, expectation value log prob-
ability associated with peptide.
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cross validation (7). The peptides identified by
MS/MS should be confirmed by a second
method, such as immunology or the use of
synthetic standards. In order to be useful in
standard MS work flows, the peptides would
have to be quantified by LC-ESI triple-stage
quadrupole or with internally or externally
standardized MS. All these important points
remain to be given consideration, but, in a
recent analysis of this field, it was suggested
that the use of antibodies presenting on a sur-
face-enhanced laser desorption/ionization
may provide greater specificity (29) as previ-
ously contemplated (30). The Human Pro-
teome Organization concluded that plasma
was the preferred blood sample (31) but has
recently indicated there was no difference (32).
Villanueva et al. (28) conclude that serum is
preferable for peptide profiling. We have used
serum for peptide profiling and protein dis-
covery (7,8). However, the best sample for a
specific purpose will likely be determined on a
case-by-case basis, and both serum and plasma
may be useful. In the present article, we turn
our attention to the use of ESI that might be
more amenable to quantitative analysis.
It may be possible to use endogenous low-
abundance peptides of serum and plasma as
biomarkers. At present, there is considerable
debate as to whether the so-called peptidome
even exists (33) and in what form (18). Pep-
tides specifically cleaved from parent molecules
that are designed to act as paracrine or
endocrine signals are likely to be present
briefly in small amounts. MS have detection
limits in the attomol range for pure sub-
stances; but, in complex mixtures, only a small
number of analytes attain useful ionization in
any one instance (8). Fibrinogen peptides have
a concentration in plasma in the nanomoles
per liter or the femtomoles per microliter.
Levels in serum should be greater. The robust
limit for automatic MS/MS identification
using our capillary LC-ESI-ion trap was about
20 fmol for a pure known peptide. A 100 pmol
mixture of three digested standard proteins
were very strongly detected and identified.
We easily detected the fibrinogens at appar-
ent concentrations of about 300 fmol per 1 µL
of serum (~300 nM). We used 100 µL of start-
ing serum for our extractions and identifica-
tions and therefore had sufficient material to
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identify fibrinogens with expectation values as
low as E-50 and other known blood proteins
with values as high as E-2. It has been sug-
gested that physiologically relevant molecules
in blood may only exist at levels less than the
detection limits of MS (34,35). However,
because the binding constants (Kd) of physio-
logically relevant proteins can be in the micro-
molar-to-nanomolar range, it would appear
that some biologically relevant molecules in
the nano- to picomolar range might be dis-
covered from small amounts of serum. 
Simple methods that have high yields and
good resolving power are required to discover
low abundance endogenous peptides. C18 chro-
matography worked well alone, or for collecting
peptides previously fractionated by precipita-
tion, filtration, or column chromatography. Thus,
the optimization of preparative chromato-
graphic materials, reagents and protocols for
the extraction of peptides from biological blood
fluids may prove to be a key step in advancing
the identification of endogenous peptides and
warrants much greater scrutiny than it has
received to date (36). The large yield of peptides
achieved by SPE permitted coupling of this
method with other separation methods in serial
combination, to explore more deeply the
endogenous peptides of serum. C18 could be
used to collect peptides from all other methods
examined. We found that SPE with C18 pro-
vided the high yield and relative reproducibility
required for discovery experiments. SPE with
C18 resin worked in a variety of formats to
extract and identify FPA. C18 microcolumns or
96-well plates with C18 magnetic beads could
be used to rapidly prepare serum for identifica-
tion of the potential biomarker FPA. C18 extrac-
tion occurs at low pH and this process will not
only extract peptides that are freely dissolved in
serum, but also those that may be noncovalently
bound to high-mass proteins.
Albumin has many cysteine residues, but we
did not observe stronger signals or different pep-
tides from serum treated with DTT. It has been
previously suggested that low-mass peptides
may noncovalently bind to higher-molecular
mass proteins, specifically BSA, and that these
interactions could be disrupted by organic sol-
vents used in ultrafiltration (20). We examined
this concept using organic solvent and ammo-
nium sulfate precipitation, dye affinity chro-
matography, size exclusion chromatography,
and ultrafiltration. We used precipitation with
acetonitrile and observed that a pool of polypep-
tides did not coprecipitate with the large-molec-
ular mass proteins. The inclusion of albumin
isolation prior to C18 extraction resulted in
sample loss and reduced the number of peptides
identified by LC-MS/MS. In agreement with
previous results, we found that ultrafiltration
could be used to detect peptides from blood (20).
We concluded that not all peptides remain
strongly bound to albumin at all times. How-
ever, peptides may potentially be bound to albu-
min or other lipoprotein complexes (14,36,37).
The intense MALDI spectral elements from
unfractionated serum or plasma represent pep-
tides from abundant circulating proteins of the
blood (7,9). Biomarker peptide patterns have
been discerned from unfractionated serum or
plasma for many diseases or physiological
states using TOF-MS, but these techniques can
also discern the differences in sample collec-
tion procedures used by sites or individuals
(6). We have previously proposed that the dif-
ferences observed in MALDI spectra between
physiological and disease states could reflect
the activity of disease-specific proteases or
enzymes released or activated in the blood that
act on blood proteins (7). Although it seems
possible that blood peptides might one day be
used for robust diagnosis via MS, it is highly
unlikely that this will be achieved without pre-
fractionation, followed by targeted assays to
quantify the peptides (6,33). It is possible that
some of the peptides in plasma or serum may
have been generated in vivo. However, previ-
ous time-course and inhibitor studies show
that MALDI patterns of abundant serum
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peptides change rapidly after blood collection
to reach ex vivo steady states that represent the
balance between the generation of peptides by
protease activity and the degradation of pep-
tides by amino and carboxy peptidases (7).
Recently, an independent group repeated our
original experiments (7) in which blood fluids
were incubated ex vivo and they came to the
same conclusion that blood peptide levels
reflect the balance of endopeptidase and exo-
peptidase activities and that this principle
might be used to detect disease specific pepti-
dase activities (28). However, we argue that
standard analytical identification, quantifica-
tion, and statistical analysis should be used
along with synthetic chromatography stan-
dards and immunological confirmation (7).
The use of SPE together with other prepara-
tion schemes, followed by LC-MS/MS, revealed
multiple isoforms of FPA bearing different
amino acid substitutions detectable by LC-
MALDI-MS/MS. For myocardial infarction, the
disease mechanism has been linked to the gen-
eration of common serum peptides, such as
FPA and C3f, and confirmed by immunological
methods (7). In the present study, we were able
to identify numerous amino acid substitutions,
and even posttranslational modification of the
FPA peptide. This may indicate that, when
combined with LC-separation, these techniques
will permit the acquisition of information about
specific peptide isoforms and modifications
from biological samples. Developing sample
preparation methods for assigning identity to
low-molecular mass peptides is of central
importance. These methods will help to trans-
form mass spectra-based diagnosis from a rela-
tive technique of comparing unknown peak
patterns (5) to a more robust method of quanti-
fying known peptides. 
The concept of a “peptidome” (38) brings up
several additional considerations for the stan-
dard of proof associated with protein identifica-
tions (39). Serum is known to contain a variety
of proteolytic enzymes including endo- and
exopeptidases. Serum contains tryptic, chy-
motryptic, metalloproteinase, and other prote-
olytic activities. Because of the effect of
constitutive amino- and carboxyl-exopeptidase
activity (7), and perhaps the apparent presence
of multiple proteases in sera (24), searches need
to be performed with no enzyme specified. Pre-
vious studies have used MS analysis of serum
and, apparently, fit the parent mass values to the
predicted cleavage products of the major blood
proteins in which a minority of peptides were
positively identified by MS/MS. In practical
experience, it is actually quite challenging to get
unbiased and automatic identification of
endogenous blood peptides by MS/MS com-
pared to tryptic digests. In this article, we only
present unbiased automatic MS/MS identifica-
tions with no inference of additional peptides by
parent mass. Peptides such as angiotensin are
single discrete polypeptide messengers that cir-
culate in the blood and act as hormones or reg-
ulatory agents. In contrast to intentional tryptic
digests, where there is a high probability of
finding multiple peptides from the same
digested protein, there is no guarantee of find-
ing multiple peptides from the same protein in
the endogenous peptides of serum. Confident
identification of single peptides of low abun-
dance is well known to be problematic and this
difficulty is further compounded by the weak
and complex signals associated with the endo-
genous peptides of serum. The confidence in
single peptides would likely be somewhat
increased by replicate identification in time (for
example, Cancer Susceptibility was detected in
multiple samples see Candidate 3, was detected
in multiple samples, see Table 2) but this is likely
not sufficient evidence because the same
misidentification may be reproducible. Common
immunological methods for proteins such as
enzyme-linked immunosorbent assay or West-
ern blot may be difficult to apply to small pep-
tides. Single antibody methods, such as dot blots
or affinity purification prior to MA, may provide
the necessary confirmation (2).
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Because there are only about 22,000 proteins
in RefSeq, but there may be approx 1 billion
variable chains associated with immunoglob-
ulins that, as a class, are a highly abundant
component of serum, we cannot entirely rule
out the possibility that peptides from variable
chains could confound mass spectral identifi-
cations in the absence of highly accurate mass
measurements. 
Detection and identification of blood pep-
tides may be confounded by biochemical
modifications. It remains possible that some
peptides were difficult to analyse or shifted in
parent mass by posttranslational modifications
in addition to C- and N-terminal exopeptidase
action that may remove basic charges and add
acidic charges, such as phosphate of sulfate,
that may effect ionization. It is known that
removing phosphorylations may increase the
ionization and detection of peptides (40). The
fibrinopeptides, for example, are well known
to be modified by both phosphorylation and
sulfation (41–45) and this may have partially
inhibited their detection. It has been suggested
that sulfonation may be useful under some
circumstances (46).
Questionable identifications of low-abun-
dance peptides could be confirmed by similar
chromatographic characteristics and fragmen-
tation of synthetic peptides, but this approach
is not useful for high-throughput discovery.
A better solution could be the use of high-
resolution MS, such as Fourier transform ion
cyclotron resonance. For peptidomics, highly
accurate parent masses combined with MS/MS
analysis may also be required to provide
highly confident predictions (47,48). If the
endogenous peptide is indeed a powerful
regulatory molecule, then it may be possible to
detect its effects by classical bioassays. A prac-
tical means of building confidence in putative
identifications may be comparison of endoge-
nous peptides identified with lists of proteins
identified from tryptic digestion of serum. For
example, the rab/rac binding protein piccolo
does not seem to be a blood protein, but simi-
lar proteins have been observed in blood
(26,49). Other proteins that also seem to make
little intuitive sense, such as the Nedd 4 bind-
ing protein, actually show significant homol-
ogy to tumor necrosis factor-α, which is known
to circulate remain unconfirmed.
A library of known endogenous peptide
analytes might be created using LC-MS/MS
and related to the changes in the intensity of a
particular parent ion in spectra from normal
and disease samples (16). In this article, we
show that with optimal sample preparation,
the peptides of biological fluids could be
identified by LC-MS/MS using ESI and
MALDI ionization. Bovine fetal serum is a
rich source of growth factors. From this fluid,
we correlated several peptides to isoforms of
the collagen superfamily, a group known to
be processed proteolytically to release power-
ful regulatory molecules (11). The ongoing
gains in sensitivity of MS indicate that the
number of endogenous peptides identified by
MS/MS from biological fluids will likely
increase in the future. To be useful, the peptides
must be unambiguously identified by mass-
accurate MS and MS/MS and quantified by
triple-quadrupole MS. Their practical applica-
bility in diagnostics remains an open question.
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